IA-2-autoantibodies complement GAD65-autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings. The Belgian Diabetes Registry.
Adolescent; Adult; Age of Onset; Autoantibodies/analysis/immunology; Belgium/epidemiology; Biological Markers/blood; Child; Child, Preschool; Cohort Studies; Diabetes Mellitus, Type 1/epidemiology/genetics/immunology; Female; Glutamate Decarboxylase/immunology; HLA-D Antigens/immunology; Humans; Islets of Langerhans/immunology; Male; Nuclear Family; Prevalence
Abstract :
[en] IA-2 has been identified as an autoantigen that is recognized by immunoglobulins from insulin-dependent diabetic (IDDM) patients. Using a liquid phase radiobinding assay, we performed an IA-2-autoantibody (IA-2-Ab) assay in 474 IDDM patients and 482 non-diabetic control subjects aged 0-3 years. IA-2-Ab were detected in 58% of the patients and 0.8% of control subjects. Their prevalence in patients was lower than that of islet cell autoantibodies (ICA; 73%) or glutamic acid decarboxylase (M(r) 65 kDa)-autoantibodies (GAD65-Ab; 82%) but higher than that of insulin autoantibodies (IAA; 42%). IA-2-Ab were more frequent in patients under age 20 years (70%) than between 20 and 40 years (45%; p < 0.001). In the whole IDDM group, 92% of patients were positive for at least one of the three molecular assays, which is higher than the positivity for the ICA assay (73%). Only 1% was negative in the molecular assays and positive in the ICA assay. IA-2-Ab levels were positively correlated with ICA titres (p < 0.001) and HLA DQ A1*0301-DQ B1*0.02 (p < 0.003) by multivariate analysis. In a group of 481 non-diabetic siblings (age 0-39 years) of IDDM patients only 7 were IA-2-Ab positive (1.5%). All seven were under age 20 years and positive for at least two other autoantibodies and for DQ A1*0301-DQB1*0302. Four of these seven developed IDDM during the 6-70-month follow-up period. The positive predictive value of IA-2-Ab (57%) was higher than that of ICA, GAD65-Ab or IAA alone, or in combination (< or = 20%) but these calculations are restricted by the relatively short observation period and the small number of cases. The only IA-2-Ab-negative case of pre-diabetes was also negative for IAA and GAD65-Ab, while it was strongly positive for ICA. In conclusion, IA-2-Ab show a high diagnostic specificity for IDDM and are predictive markers of impending diabetes in siblings of patients. In combination with other molecular antibody assays they may replace ICA testing in future. Our data also indicate that other autoantibodies than IA-2-Ab, GAD65-Ab and IAA contribute to ICA.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Gorus, F. K.
Goubert, P.
Semakula, C.
Van de Walle, Claude ; Université de Liège - ULiège > Services généraux (Faculté des sciences) > Relations académiques et scientifiques (Sciences)
De Schepper, J.
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Christie, M. R.
Pipeleers, D. G.
Language :
English
Title :
IA-2-autoantibodies complement GAD65-autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings. The Belgian Diabetes Registry.
Lu J, Li Q, Xie H et al. (1996) Identification of a second transmembrane tyrosine phosphatase, IA-2β, as an autoantigen in insulin-dependent diabetes: precursor of the 37-kDa tryptic fragment. Proc Natl Acad Sci USA 93: 2307-2311
Payton MA, Hawkes CJ, Christie MR (1995) Relationship of the 37,000- and 47,000 Mr tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA 512). J Clin Invest 96: 1506-1511
Bonifacio E, Lampasona V, Genovese S, Ferrari M, Bosi E (1995) Identification of protein tyrosine phosphatase-like IA-2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40 k autoantigen and a target of islet-cell antibodies. J Immunol 155: 5419-5426
Myers MA, Rabin DU, Rowley MJ (1995) Pancreatic islet cell cytoplasmic antibody in diabetes is represented by antibodies to islet cell antigen 512 and glutamic acid decarboxylase. Diabetes 44: 1290-1295
Van der Auwera B, Schuit F, Lyaruu I et al. (1995) Genetic susceptibility for insulin-dependent diabetes mellitus in Caucasians revisited: the importance of diabetes registries in disclosing interactions between HLA-DQ- and insulin-gene-linked risk. J Clin Endocrinol Metab 80: 2567-2573
Zweig M, Campbell G (1993) Receiver-operating characteristics (ROC) plots: a fundamental tool in clinical medicine. Clin Chem 39: 561-571
Nisticò L, Buzzetti R, Pritchard LE et al. (1996) The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Hum Mol Genet 5: 1075-1080
Morgenthaler NG, Seissler J, Achenbach P et al. (1996) Antibodies to IA-2 in IDDM, Stiff man syndrome and autoimmune endocrine diseases: evidence of high specificity for IDDM. Diabetologia 39 [Suppl I]: A27 (Abstract)
Vandewalle C, Falorni A, Goubert P, Van der Auwera B, Gorus F, the Belgian Diabetes Registry (1995) GAD65-Autoantibodies are associated with HLA-DQ- and 5′INS-linked genetic risk in adult new onset IDDM-patients. Autoimmunity 21: 31 (A119)
Verge CF, Gianani R, Kawasaki E et al. (1996) Prediction of type 1 diabetes in first-degree relatives using a combination of insulin, GAD, and ICA 512 bdc/IA-2 autoantibodies. Diabetes 45: 926-933
